An investigational medical device for the treatment of late stage lung cancer, pioneered by researchers at University of Kentucky, has been approved for clinical trials by the Food and Drug Administration (FDA). UK is the only site in the country approved to test this new treatment on advanced lung cancer patients.
The Exatherm Total Body Hyperthermia System (Exatherm-TBH) was developed at UK in a public-private partnership with Exatherm Inc. The project is supported by grant funding from the National Institutes of Health.
The research team includes Dr. Jeremiah Martin, surgical director of the UK Markey Cancer Center’s Multidisciplinary Lung Cancer Clinic; and Dr. Kevin Hatton, chief of anesthesiology critical care at UK.
A Washington State University food scientist and colleagues at Texas A&M have found that compounds in peaches can inhibit the growth of breast cancer cells and their ability to spread.
Writing in the Journal of Nutritional Biochemistry, the researchers say the compounds could be a novel addition to therapies that reduce the risk of metastasis, the primary killer in breast and many other cancers. The compounds could be given as an extract or, judging from the doses given mice in the study, two to three peaches a day.
“I would do three peaches a day,” said Giuliana Noratto, WSU assistant professor of food science.
More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris Descartes University, Paris 13 University (USPC), and Paris Diderot University have just identified the role of a new virus, hitherto unsuspected, in the occurrence of a rare type of liver cancer.
This study, based on follow-up and observation of 193 patients, is published in the 24 August issue of Nature Genetics.